Baird lowered the firm’s price target on Fate Therapeutics (FATE) to $4 from $5 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results which met expectations.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FATE:
- Fate Therapeutics price target lowered to $2 from $10 at Barclays
- Cautious Optimism for Fate Therapeutics Amid Promising Developments and Financial Stability
- Fate Therapeutics reports Q1 EPS (32c), consensus (38c)
- FATE Upcoming Earnings Report: What to Expect?
- Fate Therapeutics receives RMAT designation from FDA for FT819